You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRemifentanil
Accession NumberDB00899  (APRD01216)
TypeSmall Molecule
GroupsApproved
DescriptionRemifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is a specific mu-type-opioid receptor agonist. Hence, it causes a reduction in sympathetic nervous system tone, respiratory depression and analgesia.
Structure
Thumb
Synonyms
REMIFENTANIL
Remifentanyl
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Remifentanil for InjectionPowder, for solution2 mgIntravenousTeva Canada LimitedNot applicableNot applicableCanada
Remifentanil for InjectionPowder, for solution1 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Remifentanil for InjectionPowder, for solution1 mgIntravenousTeva Canada LimitedNot applicableNot applicableCanada
Remifentanil for InjectionPowder, for solution2 mgIntravenousSandoz Canada IncorporatedNot applicableNot applicableCanada
Remifentanil Hydrochloride for InjectionPowder, for solution5 mgIntravenousSterimax IncNot applicableNot applicableCanada
Remifentanil Hydrochloride for InjectionPowder, for solution1 mgIntravenousSterimax Inc2011-09-27Not applicableCanada
Remifentanil Hydrochloride for InjectionPowder, for solution2 mgIntravenousSterimax Inc2011-09-29Not applicableCanada
UltivaInjection, powder, lyophilized, for solution1 mg/mLIntravenousMylan Institutional LLC1996-11-06Not applicableUs
UltivaPowder, for solution2 mgIntravenousAbbvie Corporation1997-04-072013-10-02Canada
UltivaPowder, for solution5 mgIntravenousAbbvie Corporation1997-03-172013-10-02Canada
UltivaPowder, for solution1 mgIntravenousAbbvie Corporation1997-04-072013-10-02Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Remifentanil hydrochloride
ThumbNot applicableDBSALT001450
Categories
UNIIP10582JYYK
CAS number132875-61-7
WeightAverage: 376.4467
Monoisotopic: 376.199822016
Chemical FormulaC20H28N2O5
InChI KeyZTVQQQVZCWLTDF-UHFFFAOYSA-N
InChI
InChI=1S/C20H28N2O5/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2/h5-9H,4,10-15H2,1-3H3
IUPAC Name
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-phenylpropanamido)piperidine-4-carboxylate
SMILES
CCC(=O)N(C1=CC=CC=C1)C1(CCN(CCC(=O)OC)CC1)C(=O)OC
Pharmacology
IndicationFor use during the induction and maintenance of general anesthesia.
Structured Indications Not Available
PharmacodynamicsRemifentanil is an opioid agonist with rapid onset and peak effect and ultra-short duration of action. The opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone. The analgesic effects of remifentanil are rapid in onset and offset. Its effects and side effects are dose dependent and similar to other opioids. Remifentanil in humans has a rapid blood-brain equilibration half-time of 1 ± 1 minutes (mean ± SD) and a rapid onset of action.
Mechanism of actionRemifentanil is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of remifentanil is antagonized by opioid antagonists such as naloxone.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinunknown
agonist
HumanP41143 details
Kappa-type opioid receptorProteinunknown
agonist
HumanP41145 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 350 mL/kg
  • 452 ± 144 mL/kg [neonates]
  • 223 ± 30.6 mL/kg [adolescents]
Protein binding70% (bound to plasma proteins)
Metabolism

By hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases.

Route of eliminationRemifentanil is an esterase-metabolized opioid. The carboxylic acid metabolite is essentially inactive (1/4600 as potent as remifentanil in dogs) and is excreted by the kidneys with an elimination half-life of approximately 90 minutes.
Half life1-20 minutes
Clearance
  • 40 mL/min/kg [young, healthy adults]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Remifentanil Action PathwayDrug actionSMP00416
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Remifentanil is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Remifentanil.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINERemifentanil may increase the serotonergic activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Remifentanil.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Remifentanil.Approved
adipiplonThe risk or severity of adverse effects can be increased when Remifentanil is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Remifentanil.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Remifentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Remifentanil.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Remifentanil.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Remifentanil.Approved, Illicit, Investigational
AlprenololRemifentanil may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AlvimopanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Alvimopan.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Remifentanil.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amiloride.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Remifentanil.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Remifentanil.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Remifentanil which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Remifentanil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Remifentanil.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Remifentanil.Approved
Aop200704Remifentanil may increase the bradycardic activities of Aop200704.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Remifentanil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Remifentanil.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Remifentanil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Remifentanil.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Remifentanil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Asenapine.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Remifentanil.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Remifentanil.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Remifentanil.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azaperone.Vet Approved
AzelastineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Remifentanil.Approved
AzosemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Remifentanil.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Remifentanil.Approved
BefunololRemifentanil may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Remifentanil.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Remifentanil.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bendroflumethiazide.Approved
BenmoxinRemifentanil may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Remifentanil.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Remifentanil is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Remifentanil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Remifentanil.Approved
BevantololRemifentanil may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Remifentanil.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Remifentanil.Approved
BL-1020BL-1020 may increase the hypotensive activities of Remifentanil.Investigational
BopindololRemifentanil may increase the bradycardic activities of Bopindolol.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Remifentanil.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Remifentanil.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
BromazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Remifentanil.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Brotizolam.Approved, Withdrawn
BucindololRemifentanil may increase the bradycardic activities of Bucindolol.Investigational
BufuralolRemifentanil may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Remifentanil.Approved, Investigational
BupranololRemifentanil may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Remifentanil.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Remifentanil.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Remifentanil.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Remifentanil.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Remifentanil.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Canrenone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Remifentanil.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Remifentanil.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Remifentanil.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Carisoprodol.Approved
CaroxazoneRemifentanil may increase the serotonergic activities of Caroxazone.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Remifentanil.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Remifentanil.Approved, Investigational
CeliprololRemifentanil may increase the bradycardic activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Remifentanil.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Remifentanil.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Remifentanil.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Remifentanil.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Remifentanil.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Remifentanil.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Remifentanil.Approved, Vet Approved
CitalopramRemifentanil may increase the serotonergic activities of Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Remifentanil.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Remifentanil.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Remifentanil.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Remifentanil.Approved
CocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Remifentanil.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Conivaptan.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Remifentanil.Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Remifentanil.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Remifentanil.Approved
DapoxetineRemifentanil may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Remifentanil.Approved, Investigational
deramciclaneThe risk or severity of adverse effects can be increased when Remifentanil is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Desmopressin.Approved
DesvenlafaxineRemifentanil may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Remifentanil.Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Remifentanil.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Remifentanil.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Remifentanil.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Remifentanil.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Remifentanil.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Remifentanil.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Remifentanil.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Remifentanil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Remifentanil.Approved
DoxepinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Remifentanil is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Drotebanol.Experimental, Illicit
DuloxetineRemifentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Remifentanil.Approved
EcgonineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Remifentanil is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efonidipine.Approved
EluxadolineRemifentanil may increase the constipating activities of Eluxadoline.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Remifentanil.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Remifentanil.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Remifentanil.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Remifentanil.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Entacapone.Approved, Investigational
EplerenoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Remifentanil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Remifentanil.Approved
EscitalopramRemifentanil may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Remifentanil.Approved
EstazolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Remifentanil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etacrynic acid.Approved
EthanolRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Remifentanil.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Remifentanil.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Remifentanil.Approved
EtoperidoneRemifentanil may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Remifentanil.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Remifentanil.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Remifentanil.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Remifentanil.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Remifentanil.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Flunitrazepam.Approved, Illicit
FluoxetineRemifentanil may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Remifentanil.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Remifentanil.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Remifentanil.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Remifentanil.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Remifentanil.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Fospropofol.Approved, Illicit
FurazolidoneRemifentanil may increase the serotonergic activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Remifentanil is combined with gabapentin enacarbil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Remifentanil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Remifentanil.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Remifentanil.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Remifentanil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Remifentanil.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Remifentanil.Approved
HydracarbazineRemifentanil may increase the serotonergic activities of Hydracarbazine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Remifentanil.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Remifentanil.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Remifentanil.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Remifentanil.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Remifentanil.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Remifentanil.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Imipramine.Approved
IndalpineRemifentanil may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Indapamide.Approved
IndenololRemifentanil may increase the bradycardic activities of Indenolol.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Remifentanil.Withdrawn
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Remifentanil.Approved
IproclozideRemifentanil may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidRemifentanil may increase the serotonergic activities of Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Remifentanil.Approved, Investigational
IsocarboxazidRemifentanil may increase the serotonergic activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Remifentanil.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Isosorbide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Remifentanil.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Remifentanil.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Remifentanil.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Remifentanil.Approved
KetamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ketobemidone.Approved
KW-3902The risk or severity of adverse effects can be increased when Remifentanil is combined with KW-3902.Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Remifentanil.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Remifentanil.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Remifentanil.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Remifentanil.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levocetirizine.Approved
LevodopaRemifentanil may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Levomethadyl Acetate.Approved
LevomilnacipranRemifentanil may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Remifentanil.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Remifentanil.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Remifentanil.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Remifentanil.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Remifentanil.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Remifentanil.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Remifentanil.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Remifentanil.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Remifentanil.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Remifentanil is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Maprotiline.Approved
MebanazineRemifentanil may increase the serotonergic activities of Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Remifentanil.Approved
MeclizineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Remifentanil is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Remifentanil.Investigational
MephentermineMephentermine may increase the analgesic activities of Remifentanil.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Remifentanil.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Remifentanil.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Remifentanil.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Remifentanil.Approved
MethotrimeprazineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methyclothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Remifentanil.Approved
Methylene blueRemifentanil may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Remifentanil.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Remifentanil.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Remifentanil.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Remifentanil.Approved, Investigational
MetyrosineRemifentanil may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Remifentanil.Approved, Illicit
MilnacipranRemifentanil may increase the serotonergic activities of Milnacipran.Approved
MinaprineRemifentanil may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Remifentanil.Approved
MirtazapineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may increase the analgesic activities of Remifentanil.Experimental, Illicit
MoclobemideRemifentanil may increase the serotonergic activities of Moclobemide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Remifentanil.Approved
MolindoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Remifentanil.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Remifentanil.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Remifentanil.Approved
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Remifentanil.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Remifentanil.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Remifentanil.Approved
NaltrexoneThe therapeutic efficacy of Remifentanil can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Remifentanil.Approved, Investigational
NefazodoneRemifentanil may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Remifentanil.Approved, Investigational
NialamideRemifentanil may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Remifentanil.Approved
NicorandilNicorandil may increase the hypotensive activities of Remifentanil.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Remifentanil.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Remifentanil.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Remifentanil.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Remifentanil.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Remifentanil.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Remifentanil.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Remifentanil.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Remifentanil.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Remifentanil.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Remifentanil.Approved
OctamoxinRemifentanil may increase the serotonergic activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Remifentanil.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Remifentanil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Opium.Approved, Illicit
OrphenadrineRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Remifentanil is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Remifentanil.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Remifentanil.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Remifentanil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Remifentanil.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Remifentanil.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Remifentanil.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Remifentanil.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Remifentanil.Approved
ParaldehydeRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineRemifentanil may increase the serotonergic activities of Pargyline.Approved
ParoxetineRemifentanil may increase the serotonergic activities of Paroxetine.Approved, Investigational
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Remifentanil.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Remifentanil.Approved, Investigational
PentazocinePentazocine may decrease the analgesic activities of Remifentanil.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Remifentanil.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Remifentanil.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
PerazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Remifentanil.Approved
PerospironeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Remifentanil.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Remifentanil.Approved
PhenelzineRemifentanil may increase the serotonergic activities of Phenelzine.Approved
PheniprazineRemifentanil may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Remifentanil.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenoxyethanol.Approved
PhenoxypropazineRemifentanil may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Remifentanil.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Remifentanil.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Remifentanil.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Remifentanil.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Remifentanil.Approved
PiretanideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piritramide.Investigational
PirlindoleRemifentanil may increase the serotonergic activities of Pirlindole.Approved
PivhydrazineRemifentanil may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.Approved
PotassiumThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium Citrate.Approved, Vet Approved
PractololRemifentanil may increase the bradycardic activities of Practolol.Approved
PramipexoleRemifentanil may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Remifentanil.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Remifentanil.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Remifentanil.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Remifentanil.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Remifentanil.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Remifentanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Remifentanil.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Promethazine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Remifentanil.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Remifentanil.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Remifentanil.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Remifentanil.Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Remifentanil.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Remifentanil.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Remifentanil is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Remifentanil.Approved
QuazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Remifentanil.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Remifentanil.Approved
RacloprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Remifentanil.Approved
RamosetronRemifentanil may increase the constipating activities of Ramosetron.Approved
RasagilineRemifentanil may increase the serotonergic activities of Rasagiline.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Remifentanil.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Remifentanil.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Remifentanil.Approved
RisperidoneRemifentanil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Remifentanil.Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Romifidine.Vet Approved
RopiniroleRemifentanil may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Remifentanil.Approved
RotigotineRemifentanil may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Remifentanil.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Remifentanil is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sacubitril.Approved
SafrazineRemifentanil may increase the serotonergic activities of Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Remifentanil is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Remifentanil.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Remifentanil.Approved, Vet Approved
SelegilineRemifentanil may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sertindole.Approved, Withdrawn
SertralineRemifentanil may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Remifentanil.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Remifentanil.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Remifentanil is combined with Streptokinase.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Remifentanil.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Remifentanil.Approved
SuvorexantRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tasimelteon.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Remifentanil.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Remifentanil.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Remifentanil.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tetrodotoxin.Investigational
ThalidomideRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Remifentanil.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Remifentanil.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Remifentanil.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiapride.Investigational
TicrynafenThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Remifentanil.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Remifentanil.Approved
TizanidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolcapone.Approved, Withdrawn
ToloxatoneRemifentanil may increase the serotonergic activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Remifentanil.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Remifentanil is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Remifentanil.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Remifentanil.Approved
Trans-2-PhenylcyclopropylamineRemifentanil may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineRemifentanil may increase the serotonergic activities of Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Remifentanil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Remifentanil.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Remifentanil.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Remifentanil.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Remifentanil.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Remifentanil.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Remifentanil.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Remifentanil.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Remifentanil.Approved
Uc1010The risk or severity of adverse effects can be increased when Remifentanil is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Remifentanil.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Remifentanil.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Remifentanil.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Remifentanil.Approved
VenlafaxineRemifentanil may increase the serotonergic activities of Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Remifentanil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ziconotide.Approved
ZimelidineRemifentanil may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Remifentanil.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zolazepam.Vet Approved
ZolpidemRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Remifentanil is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Jacob Mathew, J. Killgore, “New methods for the synthesis of alfentanil, sufentanil, and remifentanil.” U.S. Patent US20060149071, issued July 06, 2006.

US20060149071
General ReferencesNot Available
External Links
ATC CodesN01AH06
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (380 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6136
Blood Brain Barrier+0.9381
Caco-2 permeable-0.5271
P-glycoprotein substrateSubstrate0.7345
P-glycoprotein inhibitor IInhibitor0.8682
P-glycoprotein inhibitor IINon-inhibitor0.6428
Renal organic cation transporterNon-inhibitor0.7077
CYP450 2C9 substrateNon-substrate0.8041
CYP450 2D6 substrateNon-substrate0.8786
CYP450 3A4 substrateSubstrate0.6963
CYP450 1A2 substrateNon-inhibitor0.9355
CYP450 2C9 inhibitorNon-inhibitor0.8788
CYP450 2D6 inhibitorNon-inhibitor0.8838
CYP450 2C19 inhibitorNon-inhibitor0.8201
CYP450 3A4 inhibitorNon-inhibitor0.7827
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7945
Ames testNon AMES toxic0.7388
CarcinogenicityNon-carcinogens0.8554
BiodegradationNot ready biodegradable0.9428
Rat acute toxicity2.6994 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Inhibitor0.6126
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bioniche teoranta
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionIntravenous1 mg
Powder, for solutionIntravenous2 mg
Injection, powder, lyophilized, for solutionIntravenous1 mg/mL
Powder, for solutionIntravenous5 mg
Prices
Unit descriptionCostUnit
Ultiva 5 mg vial118.15USD vial
Ultiva 2 mg vial57.2USD vial
Ultiva 1 mg vial30.19USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5019583 No1993-07-122010-07-12Us
US5866591 Yes1998-03-102018-03-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.591 mg/mLALOGPS
logP1.75ALOGPS
logP1.52ChemAxon
logS-2.8ALOGPS
pKa (Strongest Basic)7.51ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area76.15 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity100.56 m3·mol-1ChemAxon
Polarizability40.82 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Substituents
  • Alpha-amino acid or derivatives
  • Anilide
  • Piperidinecarboxylic acid
  • 4-aminopiperidine
  • Benzenoid
  • Piperidine
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Methyl ester
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Scott LJ, Perry CM: Remifentanil: a review of its use during the induction and maintenance of general anaesthesia. Drugs. 2005;65(13):1793-823. [PubMed:16114980 ]
  2. Scott LJ, Perry CM: Spotlight on remifentanil for general anaesthesia. CNS Drugs. 2005;19(12):1069-74. [PubMed:16332149 ]
  3. Warner DS, Hindman BJ, Todd MM, Sawin PD, Kirchner J, Roland CL, Jamerson BD: Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. Anesth Analg. 1996 Aug;83(2):348-53. [PubMed:8694317 ]
  4. Guy J, Hindman BJ, Baker KZ, Borel CO, Maktabi M, Ostapkovich N, Kirchner J, Todd MM, Fogarty-Mack P, Yancy V, Sokoll MD, McAllister A, Roland C, Young WL, Warner DS: Comparison of remifentanil and fentanyl in patients undergoing craniotomy for supratentorial space-occupying lesions. Anesthesiology. 1997 Mar;86(3):514-24. [PubMed:9066316 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE: Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther. 1997 Apr;281(1):226-32. [PubMed:9103501 ]
  7. Patel SS, Spencer CM: Remifentanil. Drugs. 1996 Sep;52(3):417-27; discussion 428. [PubMed:8875131 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Stucke AG, Zuperku EJ, Sanchez A, Tonkovic-Capin M, Tonkovic-Capin V, Mustapic S, Stuth EA: Opioid receptors on bulbospinal respiratory neurons are not activated during neuronal depression by clinically relevant opioid concentrations. J Neurophysiol. 2008 Nov;100(5):2878-88. doi: 10.1152/jn.90620.2008. Epub 2008 Sep 24. [PubMed:18815346 ]
  2. Rodrigues AR, Castro MS, Francischi JN, Perez AC, Duarte ID: Participation of ATP-sensitive K+ channels in the peripheral antinociceptive effect of fentanyl in rats. Braz J Med Biol Res. 2005 Jan;38(1):91-7. Epub 2005 Jan 18. [PubMed:15665994 ]
  3. Poonawala T, Levay-Young BK, Hebbel RP, Gupta K: Opioids heal ischemic wounds in the rat. Wound Repair Regen. 2005 Mar-Apr;13(2):165-74. [PubMed:15828941 ]
  4. Sahin AS, Duman A, Atalik EK, Ogun CO, Sahin TK, Erol A, Ozergin U: The mechanisms of the direct vascular effects of fentanyl on isolated human saphenous veins in vitro. J Cardiothorac Vasc Anesth. 2005 Apr;19(2):197-200. [PubMed:15868528 ]
  5. Darwish M, Tempero K, Kirby M, Thompson J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet. 2005;44(12):1279-86. [PubMed:16372825 ]
  6. Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther. 2006 May;28(5):707-14. [PubMed:16861092 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Wong GT, Li R, Jiang LL, Irwin MG: Remifentanil post-conditioning attenuates cardiac ischemia-reperfusion injury via kappa or delta opioid receptor activation. Acta Anaesthesiol Scand. 2010 Apr;54(4):510-8. doi: 10.1111/j.1399-6576.2009.02145.x. Epub 2009 Oct 29. [PubMed:19878098 ]
  2. Pascoe JE, Williams KL, Mukhopadhyay P, Rice KC, Woods JH, Ko MC: Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology. 2008 May;33(4):478-86. doi: 10.1016/j.psyneuen.2008.01.006. Epub 2008 Mar 5. [PubMed:18325678 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 03:58